JP2015520140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520140A5 JP2015520140A5 JP2015509531A JP2015509531A JP2015520140A5 JP 2015520140 A5 JP2015520140 A5 JP 2015520140A5 JP 2015509531 A JP2015509531 A JP 2015509531A JP 2015509531 A JP2015509531 A JP 2015509531A JP 2015520140 A5 JP2015520140 A5 JP 2015520140A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomer
- compound
- alkyl
- pharmaceutically acceptable
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 0 *C([C@@]1(C[C@](*)OC2)I)NC(*)=*[C@]12c(ccc(N)c1)c1N Chemical compound *C([C@@]1(C[C@](*)OC2)I)NC(*)=*[C@]12c(ccc(N)c1)c1N 0.000 description 1
- KCRIWCAXODSLRH-FGDXXIHYSA-N C[n]1nc([C@@H]2OC[C@]3(c(c(F)c4)ccc4F)N=C(N)SC[C@@H]3C2)cc1 Chemical compound C[n]1nc([C@@H]2OC[C@]3(c(c(F)c4)ccc4F)N=C(N)SC[C@@H]3C2)cc1 KCRIWCAXODSLRH-FGDXXIHYSA-N 0.000 description 1
- JYDYMWJEZLKIBS-CXMBCZLWSA-N C[n]1ncc([C@@H]2OC[C@]3(c(ccc(F)c4)c4F)N=C(N)SC[C@@H]3C2)c1 Chemical compound C[n]1ncc([C@@H]2OC[C@]3(c(ccc(F)c4)c4F)N=C(N)SC[C@@H]3C2)c1 JYDYMWJEZLKIBS-CXMBCZLWSA-N 0.000 description 1
- FEUAZHJMDOKMNX-FGDXXIHYSA-N C[n]1nccc1[C@@H]1OC[C@]2(c(c(F)c3)ccc3F)N=C(N)SC[C@@H]2C1 Chemical compound C[n]1nccc1[C@@H]1OC[C@]2(c(c(F)c3)ccc3F)N=C(N)SC[C@@H]2C1 FEUAZHJMDOKMNX-FGDXXIHYSA-N 0.000 description 1
- CTLGKGNBFWVQKZ-IXBGWNDUSA-N Cc1c[s]c([C@@H]2OC[C@]3(c(c(F)c4)ccc4F)N=C(N)SC[C@@H]3C2)n1 Chemical compound Cc1c[s]c([C@@H]2OC[C@]3(c(c(F)c4)ccc4F)N=C(N)SC[C@@H]3C2)n1 CTLGKGNBFWVQKZ-IXBGWNDUSA-N 0.000 description 1
- MWNPEMNPLJPNHT-JVMOKEISSA-N NC(SC[C@@H]1C[C@H](c2n[n](C3CC3)cc2)OC2)=N[C@]12c(c(F)c1)ccc1F Chemical compound NC(SC[C@@H]1C[C@H](c2n[n](C3CC3)cc2)OC2)=N[C@]12c(c(F)c1)ccc1F MWNPEMNPLJPNHT-JVMOKEISSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642480P | 2012-05-04 | 2012-05-04 | |
| US61/642,480 | 2012-05-04 | ||
| PCT/IB2013/053178 WO2013164730A1 (en) | 2012-05-04 | 2013-04-22 | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520140A JP2015520140A (ja) | 2015-07-16 |
| JP2015520140A5 true JP2015520140A5 (cg-RX-API-DMAC10.html) | 2016-06-16 |
| JP6110937B2 JP6110937B2 (ja) | 2017-04-05 |
Family
ID=48536971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509531A Expired - Fee Related JP6110937B2 (ja) | 2012-05-04 | 2013-04-22 | ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8962616B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2852597B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6110937B2 (cg-RX-API-DMAC10.html) |
| AR (1) | AR090928A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2872154C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2585262T3 (cg-RX-API-DMAC10.html) |
| TW (1) | TW201406765A (cg-RX-API-DMAC10.html) |
| UY (1) | UY34778A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013164730A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| CA2872154C (en) * | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2931731A1 (en) | 2012-12-11 | 2015-10-21 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014120658A1 (en) | 2013-01-29 | 2014-08-07 | Amgen Inc. | Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors |
| CA2897678A1 (en) | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) * | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| AP2015008716A0 (en) | 2013-03-08 | 2015-09-30 | Amgen Inc | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| JO3318B1 (ar) | 2013-06-18 | 2019-03-13 | Lilly Co Eli | مثبطات bace |
| US9096615B2 (en) | 2013-07-30 | 2015-08-04 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof |
| CN106459088A (zh) | 2014-04-10 | 2017-02-22 | 辉瑞公司 | 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺 |
| US9550762B2 (en) | 2014-08-08 | 2017-01-24 | Amgen, Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| MA41101A (fr) * | 2014-12-03 | 2017-10-10 | Lilly Co Eli | Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection |
| WO2017024180A1 (en) | 2015-08-06 | 2017-02-09 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| EP3353183A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides |
| WO2017051303A1 (en) * | 2015-09-24 | 2017-03-30 | Pfizer Inc. | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| WO2018112081A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| CA3047290A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| WO2018112084A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| MX388697B (es) | 2016-12-15 | 2025-03-20 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2024079733A1 (en) * | 2022-10-12 | 2024-04-18 | Adama Makhteshim Ltd. | Process for the preparation of aminopyridazine derivatives |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1308461A3 (en) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
| CA2286305A1 (en) | 1997-04-09 | 1998-10-15 | Mindset Ltd. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TR200202799T3 (tr) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | AB peptidini sekanslayan insanlaştırılmış antikorlar |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| AU2002239764B2 (en) | 2000-11-03 | 2007-06-21 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| CN1633297A (zh) | 2001-02-28 | 2005-06-29 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化哌啶衍生物 |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| WO2004032868A2 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
| WO2005025616A1 (ja) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | 抗体の用途 |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| AP2320A (en) | 2004-05-12 | 2011-11-07 | Pfizer Procucts Inc | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors. |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| AU2005247693A1 (en) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Tetraazabenzo[E]azulene derivatives and analogs thereof |
| US20050267009A1 (en) | 2004-05-28 | 2005-12-01 | Deagle William R | Method of Treatment of Acute and Persistent Pain |
| KR20070040824A (ko) | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
| EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| BRPI0609225A2 (pt) | 2005-05-12 | 2010-03-09 | Pfizer | formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CA2607499C (en) | 2005-06-22 | 2010-11-30 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| CA2624625A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| WO2007122482A1 (en) | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| HRP20110539T1 (hr) | 2006-04-21 | 2011-08-31 | Pfizer Products Inc. | PIRIDINO[3,4-b]PIRAZINONI |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| BRPI0721053A2 (pt) | 2006-11-29 | 2014-07-29 | Pfizer Prod Inc | INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE |
| AU2008208653B2 (en) | 2007-01-22 | 2012-11-22 | Pfizer Products Inc. | Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| SI2233474T1 (sl) | 2008-01-18 | 2015-11-30 | Eisai R&D Management Co., Ltd. | Kondenziran derivat aminodihidrotiazina |
| JP2011521940A (ja) | 2008-05-28 | 2011-07-28 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| WO2009144554A1 (en) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Pyrazolospiroketone acetyl-c0a carboxylase inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| ES2539859T3 (es) | 2008-09-30 | 2015-07-06 | Eisai R&D Management Co., Ltd. | Nuevo derivado de aminodihidrotiazina condensado |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| PL2406253T3 (pl) | 2009-03-11 | 2013-10-31 | Pfizer | Pochodne benzofuranylu jako inhibitory glukokinazy |
| CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
| EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
| JP2012526096A (ja) | 2009-05-08 | 2012-10-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| US20100285145A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| WO2011071109A1 (ja) * | 2009-12-11 | 2011-06-16 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| EP2751116B1 (en) * | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| CA2872154C (en) * | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
| CA2897678A1 (en) * | 2013-02-13 | 2014-08-21 | Pfizer Inc. | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CN111772834B (zh) | 2014-03-21 | 2022-07-15 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
-
2013
- 2013-04-22 CA CA2872154A patent/CA2872154C/en not_active Expired - Fee Related
- 2013-04-22 EP EP13725822.4A patent/EP2852597B1/en not_active Not-in-force
- 2013-04-22 JP JP2015509531A patent/JP6110937B2/ja not_active Expired - Fee Related
- 2013-04-22 WO PCT/IB2013/053178 patent/WO2013164730A1/en not_active Ceased
- 2013-04-22 ES ES13725822.4T patent/ES2585262T3/es active Active
- 2013-05-02 TW TW102115730A patent/TW201406765A/zh unknown
- 2013-05-03 UY UY0001034778A patent/UY34778A/es unknown
- 2013-05-03 US US13/886,405 patent/US8962616B2/en not_active Expired - Fee Related
- 2013-05-03 AR ARP130101513A patent/AR090928A1/es unknown
-
2015
- 2015-01-09 US US14/593,587 patent/US20150133438A1/en not_active Abandoned